• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

作者信息

Bellone S, Roque D M, Siegel E R, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D-A, Huang G S, Andikyan V, Damast S, Clark M, Azodi M, Schwartz P E, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov L B, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A D

机构信息

Smilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.

Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA.

出版信息

Ann Oncol. 2021 Aug;32(8):1045-1046. doi: 10.1016/j.annonc.2021.04.013. Epub 2021 Apr 28.

DOI:10.1016/j.annonc.2021.04.013
PMID:33932502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9465821/
Abstract
摘要

相似文献

1
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).帕博利珠单抗用于具有林奇样特征与MLH-1甲基化特征的复发性微卫星高度不稳定（MSI-H）子宫内膜癌患者的II期评估（NCT02899793）。
Ann Oncol. 2021 Aug;32(8):1045-1046. doi: 10.1016/j.annonc.2021.04.013. Epub 2021 Apr 28.
2
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.帕博利珠单抗治疗复发性林奇样型与散发型微卫星不稳定型子宫内膜癌的 2 期评估。
Cancer. 2022 Mar 15;128(6):1206-1218. doi: 10.1002/cncr.34025. Epub 2021 Dec 7.
3
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.派姆单抗治疗晚期复发性子宫内膜癌的成本效果分析。
Gynecol Oncol. 2019 May;153(2):381-384. doi: 10.1016/j.ygyno.2019.02.013. Epub 2019 Feb 24.
4
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.PD-1抑制剂瑞替凡利单抗在复发的微卫星高度不稳定或错配修复缺陷子宫内膜癌患者中的抗肿瘤活性和安全性：POD1UM-101 I期研究队列H的最终安全性和疗效结果
Gynecol Oncol. 2024 Jul;186:191-198. doi: 10.1016/j.ygyno.2024.05.025. Epub 2024 Jun 1.
5
Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.帕博利珠单抗对比化疗治疗既往治疗后存在错配修复缺陷或高度微卫星不稳定不可切除或转移性子宫内膜癌的美国女性患者的成本效果分析。
J Med Econ. 2021 Jan-Dec;24(1):675-688. doi: 10.1080/13696998.2021.1917140.
6
[New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].[新药获批：多斯塔利单抗——用于晚期微卫星高度不稳定子宫内膜癌的二线治疗]
Bull Cancer. 2021 Jul-Aug;108(7-8):675-676. doi: 10.1016/j.bulcan.2021.04.006. Epub 2021 May 14.
7
Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.妇科恶性肿瘤帕博利珠单抗微卫星高度不稳定伴随诊断检测的临床和病理分析。
Jpn J Clin Oncol. 2022 Feb 5;52(2):128-133. doi: 10.1093/jjco/hyab175.
8
A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.患者存在 MSH6 胚系突变致林奇综合征，使用派姆单抗治疗后获得持久缓解：一例子宫浆液性癌病例报告
Oncologist. 2021 Oct;26(10):811-817. doi: 10.1002/onco.13832. Epub 2021 Jun 14.
9
Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.肥胖与帕博利珠单抗治疗的微卫星不稳定高子宫内膜癌患者无进展生存期的改善相关。
Gynecol Oncol. 2024 Jan;180:139-145. doi: 10.1016/j.ygyno.2023.11.033. Epub 2023 Dec 12.
10
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.多塔利单抗治疗子宫内膜癌的安全性、有效性和生物标志物分析：GARNET 研究的 I 期结果的中期分析。
Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915.

引用本文的文献

1
Diagnostic performance of radiomics models for preoperative prediction of microsatellite instability status in endometrial cancer: a systematic review and meta-analysis.放射组学模型对子宫内膜癌微卫星不稳定性状态术前预测的诊断性能：一项系统评价和荟萃分析
Abdom Radiol (NY). 2025 Apr 8. doi: 10.1007/s00261-025-04933-9.
2
Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials.PD-1/PD-L1抑制剂在晚期或复发性子宫内膜癌中的疗效和安全性：一项随机对照试验的Meta分析及试验序贯分析
Front Immunol. 2025 Jan 31;16:1521362. doi: 10.3389/fimmu.2025.1521362. eCollection 2025.
3
Establishment and verification of a prognostic signature associated with fatty acid metabolism in endometrial cancer.子宫内膜癌中与脂肪酸代谢相关的预后特征的建立与验证
Mol Med Rep. 2025 Mar;31(3). doi: 10.3892/mmr.2025.13444. Epub 2025 Jan 31.
4
Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.子宫内膜癌全景：分子机制、生物标志物与靶向治疗
Cancers (Basel). 2024 May 27;16(11):2027. doi: 10.3390/cancers16112027.
5
Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.PD-1/PD-L1抑制剂单药治疗子宫内膜癌患者的有效性和安全性。
Discov Oncol. 2024 May 15;15(1):168. doi: 10.1007/s12672-024-01033-w.
6
A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.两种途径的故事：DNA 错配修复缺陷和微卫星不稳定高的子宫内膜癌中免疫检查点抑制剂的综述。
Cancer. 2024 May 15;130(10):1733-1746. doi: 10.1002/cncr.35267. Epub 2024 Feb 29.
7
Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.PD-1/PD-L1抑制剂在晚期或复发性子宫内膜癌中的有效性和安全性：一项系统评价与荟萃分析
Front Pharmacol. 2023 Dec 14;14:1330877. doi: 10.3389/fphar.2023.1330877. eCollection 2023.
8
Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening-A Critical Appraisal.甲基化检测作为子宫内膜癌通用筛查的重要组成部分——批判性评估
Cancers (Basel). 2023 Oct 28;15(21):5188. doi: 10.3390/cancers15215188.
9
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance.PD-1 和 PD-L1 在子宫内膜癌中的表达：分子和临床意义。
Int J Mol Sci. 2023 Oct 16;24(20):15233. doi: 10.3390/ijms242015233.
10
Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.针对晚期复发性子宫内膜癌中PD-1/PD-L1通路的免疫检查点抑制剂：一项基于SWOT分析的范围综述
Cancers (Basel). 2023 Sep 19;15(18):4632. doi: 10.3390/cancers15184632.

本文引用的文献

1
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.微卫星不稳定型子宫内膜癌的免疫微环境：遗传或散发性起源很重要。
Clin Cancer Res. 2017 Aug 1;23(15):4473-4481. doi: 10.1158/1078-0432.CCR-16-2655. Epub 2017 Mar 6.
2
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.子宫和卵巢癌肉瘤的突变图谱表明组蛋白基因与上皮-间质转化有关。
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. doi: 10.1073/pnas.1614120113. Epub 2016 Oct 10.
3
Classification and characterization of microsatellite instability across 18 cancer types.18 种癌症中微卫星不稳定性的分类和特征描述。
Nat Med. 2016 Nov;22(11):1342-1350. doi: 10.1038/nm.4191. Epub 2016 Oct 3.